Table 2.
Evolution of the parameters of evaluation of the secondary objectives of the study.
| Group | Basal (n) % | W48 (n) % | Difference Basal-W52 | p* | |
|---|---|---|---|---|---|
| Analytical data | |||||
| Controlled disease (CD4 Count > 200 cel/mcL and undetectable viral load) | Control | (7/9) 77.8% | (5/9) 55.6% | -22.2% | 0.625 |
| Intervention | (9/14) 64.3% | (12/14) 85.7% | 21.4% | 0.250 | |
| Lifestyle habits data | |||||
| Patient with drug consume | Control | (1/9) 11.1% | (1/9) 11.1% | 0.0% | 1.000 |
| Intervention | (2/14) 14.3% | (2/14) 14.3% | 0.0% | 1.000 | |
| Patient with alcohol consume | Control | (3/9) 33.3% | (4/9) 44.4% | 11.1% | 1.000 |
| Intervention | (2/14)14.3% | (1/14) 7.1% | -7.2% | 1.000 | |
| Smoking Patients | Control | (7/9) 77.8% | (7/9) 77.8% | 0.0% | 1.000 |
| Intervention | (6/14) 42.9% | (5/14) 35.7% | -7.2% | 1.000 | |
| RCVa [median (RIQ)] | Control (n=9) | 7 (5-14) | 4 (1.5-7) | -3 | 0.075 |
| Intervention (n=14) | 11 (6.5-15.3) | 2 (1-4.3) | -9 | 0.005 | |
| Adherence | |||||
| ARTbAdherence | Control | (7/9) 77.8% | (5/9) 55.6% | -22.20% | 0.625 |
| Intervention | (10/14) 71.4% | (14/14) 100% | 28.60% | 0.125 | |
| Concomitant Medication Adherence | Control | (4/9) 44.4% | (2/9) 22.2% | -22.20% | 0.368 |
| Intervention | (5/14) 35.7% | (9/14) 64.3% | 28.60% | 0.135 | |
| Global Adherence | Control | (5/9) 55.6% | (3/9) 33.3% | -22.3% | 0.625 |
| Intervention | (5/14) 35.7% | (11/14) 80.6% | 44.90% | 0.031 | |
| Medication Regimen Complexity Index | |||||
| MRCIcART [median (RIQ)] | Control | 4 (3-4.5) | 4 (3-4) | 0.0 | 0.317 |
| Intervention | 4 (3.8-5.5) | 4 (3.6-6) | 0.0 | 0.807 | |
| MRCI co-ARTd[median (RIQ)] | Control | 10 (9.8-11.0) | 1 (0.5-5) | -9.0 | 0.008 |
| Intervention | 13 (8-17) | 1.5 (1-5.3) | -11.5 | 0.001 | |
| MRCI Global [median (RIQ)] | Control | 14 (13-15.3) | 2 (1-5.5) | -12.0 | 0.008 |
| Intervention | 17 (11.9-22.3) | 1 (1-2) | -16.0 | 0.001 | |
| Polypharmacy | Control | (5/9) 55.6% | (4/9) 44.4% | -10.6% | 1.000 |
| Intervention | (9/14) 64.3% | (6/14) 42.9% | -21.4% | 0.453 | |
*
Intragroup differences were assessed pre vs. post intervention by McNemar test or Wilcoxon test for dichotomic and quantititatives variables, respectively.aCardiovascular risk; bAntiretroviral treatment; cMedication regimen complexity index; dConcomitant medication.